A detailed history of Ubs Asset Management Americas Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 83,074 shares of PCRX stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,074
Previous 105,913 21.56%
Holding current value
$1.62 Million
Previous $3.03 Million 58.71%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$11.7 - $28.46 $267,216 - $649,997
-22,839 Reduced 21.56%
83,074 $1.25 Million
Q2 2024

Aug 13, 2024

BUY
$25.5 - $31.51 $1.42 Million - $1.76 Million
55,777 Added 111.25%
105,913 $3.03 Million
Q3 2023

Nov 13, 2023

BUY
$30.68 - $40.09 $71,361 - $93,249
2,326 Added 4.87%
50,136 $1.54 Million
Q1 2023

May 15, 2023

BUY
$35.53 - $43.38 $164,077 - $200,328
4,618 Added 10.69%
47,810 $1.95 Million
Q3 2022

Nov 14, 2022

SELL
$51.24 - $58.89 $550,061 - $632,184
-10,735 Reduced 19.91%
43,192 $2.3 Million
Q2 2022

Aug 12, 2022

BUY
$51.49 - $81.64 $27,032 - $42,861
525 Added 0.98%
53,927 $3.14 Million
Q1 2022

May 16, 2022

BUY
$60.03 - $76.49 $150,735 - $192,066
2,511 Added 4.93%
53,402 $4.08 Million
Q2 2021

Aug 16, 2021

BUY
$59.18 - $69.99 $217,782 - $257,563
3,680 Added 7.79%
50,891 $3.09 Million
Q1 2021

May 14, 2021

SELL
$59.31 - $78.82 $24,969 - $33,183
-421 Reduced 0.88%
47,211 $3.31 Million
Q4 2020

Mar 01, 2021

BUY
$50.47 - $66.26 $172,859 - $226,940
3,425 Added 7.75%
47,632 $2.85 Million
Q3 2020

Nov 13, 2020

BUY
$51.97 - $63.0 $133,458 - $161,784
2,568 Added 6.17%
44,207 $2.66 Million
Q2 2020

Aug 14, 2020

SELL
$30.8 - $52.47 $185,970 - $316,813
-6,038 Reduced 12.66%
41,639 $2.18 Million
Q1 2020

May 15, 2020

SELL
$28.4 - $50.7 $5,594 - $9,987
-197 Reduced 0.41%
47,677 $1.6 Million
Q4 2019

Feb 14, 2020

BUY
$36.31 - $46.83 $8,750 - $11,286
241 Added 0.51%
47,874 $2.17 Million
Q3 2019

Nov 14, 2019

BUY
$35.66 - $44.99 $145,778 - $183,919
4,088 Added 9.39%
47,633 $1.81 Million
Q2 2019

Aug 15, 2019

BUY
$36.57 - $47.97 $276,542 - $362,749
7,562 Added 21.02%
43,545 $0
Q1 2019

May 14, 2019

BUY
$36.47 - $42.17 $59,920 - $69,285
1,643 Added 4.78%
35,983 $0
Q4 2018

Feb 13, 2019

BUY
$41.31 - $52.16 $205,847 - $259,913
4,983 Added 16.97%
34,340 $1.48 Million
Q2 2018

Aug 14, 2018

BUY
$27.5 - $39.8 $94,215 - $136,354
3,426 Added 13.21%
29,357 $0
Q1 2018

May 14, 2018

BUY
$29.98 - $46.35 $210,789 - $325,886
7,031 Added 37.2%
25,931 $0
Q4 2017

Feb 09, 2018

SELL
$31.85 - $46.95 $177,213 - $261,229
-5,564 Reduced 22.74%
18,900 $0
Q3 2017

Nov 13, 2017

BUY
$35.7 - $39.5 $873,364 - $966,328
24,464
24,464 $0

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.